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Behavioral/Cognitive
Effort-Related Motivational Effects of the VMAT-2 Inhibitor
Tetrabenazine: Implications for Animal Models of the
Motivational Symptoms of Depression
Eric J. Nunes,1 Patrick A. Randall,1 Evan E. Hart,1 Charlotte Freeland,1 Samantha E. Yohn,1 Younis Baqi,2
Christa E. Mu¨ller,2 Laura Lo´pez-Cruz,3 Merce` Correa,1,3 and John D. Salamone1
1Department of Psychology, University of Connecticut, Storrs, Connecticut 06269-1020, 2Universita¨t Bonn, Pharma-Zentrum Bonn, Pharmazeutisches
Institut, Pharmazeutische Chemie, 53121 Bonn, Germany, and 3A`rea de Psicobiologia, Campus de Riu Sec, Universitat Jaume I, 12071 Castello´, Spain
Motivated behaviors are often characterized by a high degree of behavioral activation, and work output and organisms frequently
make effort-related decisions based upon cost/benefit analyses.Moreover, people withmajor depression and other disorders often show
effort-relatedmotivational symptoms such as anergia, psychomotor retardation, and fatigue. It has been suggested that tasksmeasuring
effort-related choice behavior could be used as animal models of the motivational symptoms of depression, and the present studies
characterized the effort-related effects of the vesicular monoamine transport (VMAT) inhibitor tetrabenazine. Tetrabenazine produces
depressive symptoms in humans and, because of its selective inhibition of VMAT-2, it preferentially depletes dopamine (DA). Rats were
assessed using a concurrent fixed-ratio 5/chow feeding choice task that is known to be sensitive to dopaminergic manipulations. Tetra-
benazine shifted response choice in rats, producing a dose-related decrease in lever pressing and a concomitant increase in chow intake.
However, it did not alter food intake or preference in parallel free-feeding choice studies. The effects of tetrabenazine on effort-related
choice were reversed by the adenosine A2A antagonistMSX-3 and the antidepressant bupropion. A behaviorally active dose of tetrabena-
zine decreased extracellular DA in nucleus accumbens and increased expression of DARPP-32 in accumbensmedium spiny neurons in a
pattern indicative of reduced transmission at both D1 and D2 DA receptors. These experiments demonstrate that tetrabenazine, which is
used in animalmodels to produce depression-like effects, can alter effort-related choice behavior. These studies have implications for the
development of animal models of the motivational symptoms of depression and related disorders.
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Introduction
To survive, organisms must overcome obstacles separating them
from motivational stimuli and make effort-related decisions
based upon cost/benefit analyses (Salamone and Correa, 2002,
2012). There is considerable interest in characterizing the neural
circuitry underlying effort-based processes in animals (Salamone
et al., 1997, 2007; Walton et al., 2003; Cagniard et al., 2006; Flo-
resco and Ghods-Sharifi, 2007; Mingote et al., 2008; Hauber and
Sommer, 2009; Salamone and Correa, 2012; Nunes et al., 2013a;
Pasquereau andTurner, 2013) and humans (Croxson et al., 2009;
Kurniawan et al., 2010; Wardle et al., 2011; Treadway et al.,
2012a). Effort-based decision making is studied with tasks offer-
ing choices between high effort options leading to highly valued
reinforcers versus low effort/low reward options. In animal stud-
ies, such tasks include operant procedures offering choices be-
tween responding on ratio schedules for preferred reinforcers
versus approaching and consuming a less preferred food (Salam-
one et al., 1991, 2002; Randall et al., 2012), a T-maze barrier
crossing task (Salamone et al., 1994;Mott et al., 2009; Pardo et al.,
2012), and effort discounting (Floresco et al., 2008; Bardgett et
al., 2009). Considerable research has focused on the effort-related
functions of dopamine (DA) systems, particularly accumbens
DA. Across multiple tasks, low doses of DA antagonists and ac-
cumbens DA depletions or antagonism shift choice behavior,
decreasing selection of high effort/high reward options, and in-
creasing selection of low effort/low reward choices (Salamone et
al., 1994, 1997, 2007; Nowend et al., 2001).
People with depression and related disorders commonly show
profoundmotivational impairments, including psychomotor retar-
dation, anergia, lassitude, and fatigue, which can be highly resistant
to treatment (Stahl, 2002; Bella et al., 2010). Tasksmeasuring effort-
based functions have been suggested as potential models for these
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motivational symptoms (Salamone et al., 2006, 2007). Tests of ef-
fort-related decision making have been developed in humans
(Treadway et al., 2009), and depressed patients show reduced selec-
tion of high effort alternatives (Treadway et al., 2012b). The present
work investigated the effort-related effects of tetrabenazine, a selec-
tive and reversible inhibitor of vesicular monoamine transporter-2
(VMAT-2). Tetrabenazine blocks storage and depletes mono-
amines, but its greatest impact is upon striatal DA (Pettibone et al.,
1984;Tanra et al., 1995).Tetrabenazine is used to treatHuntington’s
disease, but depressive symptoms including fatigue are major side
effects (Frank, 2009, 2010). Moreover, tetrabenazine has frequently
been used in studies involving animal models of depression (Pres-
korn et al., 1984; Kent et al., 1986; Wang et al., 2010). The present
studies assessed the effort-related effects of tetrabenazine in rats us-
ing the concurrent fixed ratio 5 (FR5) lever-pressing/chow-feeding
choice task (Salamone et al., 1991, 2002, 2009). It was hypothesized
that low systemic doses and intra-accumbens injections of tetra-
benazine would alter choice behavior, decreasing lever pressing but
increasing consumption of the concurrently available chow. The
adenosine A2A antagonist MSX-3 [(E)-phosphoric acid mono-[3-
[8-[2-(3-methoxyphenyl)vinyl]-7-methyl-2,6-dioxo-1-prop-2-
ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] ester disodium salt]and
the antidepressant bupropion were assessed for their ability to re-
verse the effects of tetrabenazine. Additional studies determined the
effectof tetrabenazineonextracellularDAusingmicrodialysismeth-
ods andDA-related signal transduction activity using immunocyto-
chemistry for phosphorylated DARPP-32.
Materials andMethods
Animals
Adult male Sprague Dawley rats (Harlan-Sprague Dawley) were pair
housed in a colony maintained at 23°C with 12 h light/dark cycles (lights
on at 7:00 h). Rats (N 129) weighed 290–340 g at the beginning of the
study and were initially food restricted to 85% of their free-feeding body
weight for operant training. Rats were fed supplemental chow to main-
tain the food restriction throughout the study, given water ad libitum,
and allowed modest weight gain throughout the experiments. Animal
protocols were approved by the University of Connecticut institutional
animal care and use committee and followed National Institutes of
Health guidelines.
Pharmacological agents
Tetrabenazine [(R,R)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexa-
hydro-pyrido[2,1-a]isoquinolin-2-one] and bupropion [(RS)-1-(3-chlor-
phenyl)-2-tert-butylamino-propan-1-on hydrochloride] were obtained
from Tocris Bioscience. Tetrabenazine was dissolved in a 10% dimethyl
sulfoxide (DMSO) solutionmixedwith saline andpHadjustedwith 1NHCl
to bring the final solution to pH 3.5. The 10% DMSO solution used to
dissolve the tetrabenazine served as the vehicle control. Doses of tetrabena-
zine used were based on previous data and pilot studies. Bupropion was
dissolved in 0.9% saline. MSX-3 was provided by Christa Mu¨ller at the
Pharmazeutisches Institut, Universita¨t Bonn, in Bonn, Germany (Hock-
emeyer et al., 2004).MSX-3 (free acid) was dissolved in 0.9% saline and pH
was adjusted by titrating with microliter quantities of 1.0 N NaOH until the
drugwas in solution.The final pHwasusually 7.50.2 andwasnot allowed
to exceed 7.8. Doses were selected based upon pilot experiments and previ-
ous studies; the doses of MSX-3 selected have been shown previously to
reverse DA antagonist-induced impairments in FR5 lever pressing and ef-
fort-relatedchoice (Farrar et al., 2007;Wordenet al., 2009),butdidnotaffect
FR5/chow-feeding performance when administered alone (Farrar et al.,
2007).
Behavioral procedures
Behavioral sessions were conducted in operant conditioning chambers
(28  23  23 cm; Med Associates). Rats were initially trained to lever
press on a continuous reinforcement schedule (30 min sessions for 5 d)
reinforced by high carbohydrate 45 mg pellets (Bio-serv) and were then
shifted to the FR5 schedule (30 min sessions 5 d/week) and trained for 5
additional weeks. Rats were then trained on the concurrent FR5/chow-
feeding procedure (Salamone et al., 2002; Nunes et al., 2010). Weighed
amounts of laboratory chow (5P00 Laboratory Diet; Prolab or RHM
3000; Purina Mills; typically 15–20 g in 3 large pieces) were concurrently
available on the floor of the chamber during the FR5 sessions. After the
session, rats were immediately removed from the chambers and food
intake was determined by weighing the remaining food (including spill-
age). Rats were trained until they attained stable levels of baseline lever
pressing and chow intake (i.e., consistent responding over 1200 lever
presses per 30 min; typically 3 weeks), after which time drug testing
began. Formost baseline days, rats did not receive supplemental feeding;
however, over weekends and after drug tests, rats usually received addi-
tional chow in the home cage. On baseline and drug treatment days, rats
normally consumed all the operant pellets that were delivered from lever
pressing during each session. For the food preference study, rats were
trained for several weeks in 30min sessions inwhich both Bio-serv pellets
and laboratory chow were available for consumption. At the end of the
session, rats were immediately removed from the chambers and food
intake was determined by weighing the remaining food (including
spillage).
Surgery
For intracranial injections, rats received bilateral implantation of guide
cannulaemadewith 25 gauge extra-thin-wall stainless steel tubing (Small
Parts), which were implanted 1.0 mm dorsal to the target site at the
following coordinates: accumbens core (AP1.6 mm from the bregma,
ML 1.4 mm from the midline, DV 6.8 mm from the skull surface;
incisor bar 5.0 mm above the interaural line); control site 3.0 mm
dorsal to the accumbens core (AP1.6 mm from the bregma, ML1.4
mm from the midline, DV3.8 mm from the skull surface; incisor bar
5.0 mm above the interaural line). Animals were anesthetized with
injection of a solution (1.0 ml/kg, i.p.) that was prepared by mixing 10.0
ml of 100.0 mg/ml ketamine and 0.75 ml of 20.0 mg/ml xylazine and
placed in a stereotaxic device (David Kopf Instruments). For the micro-
dialysis experiment, the tips of the guide cannulae (Bioanalytical Sys-
tems) were implanted 2.0 mm dorsal to the accumbens core (AP 2.8
mm, ML 1.4 mm, DV 5.8 mm from bregma). All guide cannulae
were secured to the skull by stainless steel screws and cranioplastic ce-
ment and a stainless steel stylet was inserted through each guide cannula
to insure its integrity. After surgery, animals were allowed to recover for
a minimum of 7 d before testing.
Nissl staining for identifying cannula placements
At the completion of behavioral testing in the intracranial injection and
microdialysis experiments, each animal was anesthetized with CO2 and
then perfused intracardially with physiological saline followed by a 3.7%
formaldehyde solution. The brains were removed and stored in formal-
dehyde and then sliced with a cryostat in 50 m sections, which were
mounted on glass microscope slides. After mounting, slides were stained
with cresyl violet for microscopic observation by an observer who was
unaware of the experimental treatment. Any animal with improper can-
nulae placement or significant damage around the injection site was
excluded from the statistical analyses of behavioral data.
DA microdialysis
On themornings of sample collection days, dialysis probes (Bioanalytical
Systems) were inserted through the microdialysis guide cannulae. Arti-
ficial CSF (aCSF; 147.2 mM NaCl, 2.4 mM CaCl2, 4.0 mM KCl) was
continuously perfused through the probe at a rate of 2.0 l/min. Neuro-
chemical samples were collected every 30 min in microcentrifuge tubes
that contained 2.0l of 70% perchloric acid to prevent oxidation of DA.
Twelve samples were collected through the day at an interval of 30 min
for each collection tube. Starting 2 h after the initial insertion of the
probe, the first 5 samples were collected before the intraperitoneal injec-
tion of 0.75mg/kg tetrabenazine to establish a stable DA level and the last
2 of those baseline samples were used as the statistical baseline. Samples
were frozen and analyzed for DA using reverse-phase high-performance
liquid chromatography with electrochemical detection (ESA). The elec-
trochemical parameters were as follows: channel 1100 mV, channel
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2200 mV, guard cell350 mV. Each liter of mobile phase con-
tains 27.5 g sodium phosphate monobasic, 7.0%methanol, 750 l of 0.1
M EDTA, and 2200l of 0.4 M sodiumoctyl sulfate dissolved in deionized
ultrapure H2O with a final pH of 4.5. The flow rate was 1.0 ml/min. DA
standards were run before, during, and after the dialysate samples. Probe
placements were verified with histological analyses and only probes with
placement in the nucleus accumbens core were used for these analyses.
cFos and DARPP-32 immunohistochemical methods
After drug treatments (see below), the animals in Experiments 7–9 were
anesthetized with CO2 and transcardially perfused with 0.9% physiolog-
ical saline for 5min, followed by perfusion with 3.7% formaldehyde for 5
min. Brains were fixed for 24 h by immersion in 3.7% formaldehyde and
then transferred into a 30% sucrose solution for 48 h at 4°C before brain
sectioning. Free floating coronal sections of brains (50 m) were serially
cut using a Cryostat 9 (Thermo Fisher) and rinsed in 0.01 M phosphate
buffer (PBS). To measure the immunoreactivity to phosphorylated DA
and c-AMP-regulated phosphoprotein 32 kDa (pDARPP-32), nonspe-
cific binding sites were blocked, and cells were permeabilized in a solu-
tion containing 0.1% Triton X-100 (T.X), 10% normal donkey serum
(NDS) in PBS for 30 min at room temperature on a rotating platform
before primary antibody incubation. pDARPP-32 immunoreactivity was
visualized with a polyclonal rabbit antibody for pDARPP-32 phosphor-
ylated at the threonine 34 residue (Thr34, 1:1000; Santa Cruz Biotech-
nology), or polyclonal rabbit antibody for pDARPP-32 phosphorylated
at the threonine 75 residue (Thr75, 1:1000; Santa Cruz Biotechnology).
These antibodies were dissolved in solutions that also contained 10%
NDS and 0.1%T.X in PBS for 48 h incubation on a rotating shaker at 4°C.
After the primary antibody treatment, the sections were rinsed in PBS (3
times for 5 min) and incubated in the secondary antibody, anti-rabbit
HRP conjugate envision plus (DAKO) for 2 h on a rotating shaker at
room temperature. Finally, sections were washed and rinsed for 3–5min
in 3,3 diaminobenzidine chromagen. The sections were then mounted
to gelatin-coated slides, air dried, and coverslipped using Cytoseal 60
(Thermo Scientific) as a mounting medium. The tissue was then exam-
ined by lightmicroscopy. The processing of the c-Fos tissuewas similar to
the procedures described for pDARPP-32,with themain difference being
the blocking step, which consisted of a solution of 0.3% H2O2 and 1%
bovine serum albumin, and the use of a c-Fos specific primary antibody
(rabbit polyclonal anti c-Fos, 1:5000; Calbiochem).
Quantification of DARPP-32 and c-Fos-positive cells
Quantification of the number of cells that express immunoreactivity
for c-Fos in nucleus accumbens core and pDARPP-32(Thr34) and
pDARPP-32(Thr75) in the nucleus accumbens core and shell was per-
formed by photographing the sections with a 20 (0.125 mm2/field)
objective (Eclipse E600; Nikon) upright microscope equipped with an
Insight Spot digital camera (Diagnostic Instruments). Images of the re-
gions of interest were magnified at 20 and captured digitally using
SPOT software. Cells that were positively labeled for pDARPP-
32(Thr34), pDARPP-32(Thr75), or c-Fos were quantified with ImageJ
software (version 1.42) and a macro written to automate particle count-
ing within the region of interest. The size of the region of interest was
1000 1000 m. For each animal, cell counts were at levels that corre-
spond to 0.70–1.70 mm anterior to bregma (Paxinos andWatson, 1997)
bilaterally from at least three sections and counts were averaged across
slides and sections.
Immunofluorescence double-labeling studies of DARPP-32,
substance P, and enkephalin
Free-floating coronal sections of brains (50m) were serially cut using a
cryostat and rinsed in 0.01 M PBS. To measure the immunoreactivity to
pDARPP-32, nonspecific binding sites were blocked and cells were per-
meabilized in a solution containing 0.1%T.X and 10%NDS inPBS for 30
min at room temperature on a rotating platform before primary anti-
body incubation. pDARPP-32 immunoreactivity was visualized with a
polyclonal rabbit antibody for pDARPP-32(Thr34) (1:500; Santa Cruz
Biotechnology) or polyclonal rabbit antibody for pDARPP-32(Thr75)
(1:500; Santa Cruz Biotechnology). The different forms of pDARPP-32
were double labeled with primary antibodies for substance P (goat poly-
clonal, 1:400; Santa Cruz Biotechnology) or enkephalin (mouse mono-
clonal, 1:400; Millipore). These antibodies were dissolved in solutions
that also contained 10%NDS and 0.1% T.X in PBS for a 48 h incubation
on a rotating shaker at 4°C. After the primary antibody treatment, the
sections were rinsed in PBS (3 times for 5 min) and incubated in the
secondary antibody solution containing donkey anti-rabbit Alexa Fluor
488 (1:500; Life Technologies) and donkey anti-goat Alexa Fluor 594
(1:500; Life Technologies) or donkey anti-mouse Alexa Fluor 594 (1:500;
Life Technologies). These antibodies were dissolved in solutions that also
contained 10% NDS and 0.1% T.X in PBS for a 2 h incubation on a
rotating shaker at 22°C. The sections were then mounted to gelatin-
coated slides, air dried, and coverslipped using ProLong Gold antifade
medium (Life Technologies). Immunofluorescence staining was visual-
ized for high-resolution observation on an Axio Imager M2 upright flu-
orescent microscope (Carl Zeiss), photographed with a Hamamatsu
ORCA-R2 C10600 digital camera, and analyzed with Stereo Investigator
software (MicroBrightField).
Behavioral experiments
Rats were trained on the concurrent FR5/chow-feeding procedure (as
described above) before testing began and each experiment used differ-
ent groups of rats. Experiments 1–4 used a within-groups design, with
each rat receiving intraperitoneal drug treatments in their particular ex-
periment in a randomly varied order (one treatment per week, with none
of the treatment sequences repeated across different animals in the same
experiment). Baseline (i.e., nondrug) sessions were conducted an addi-
tional 4 d per week. Behavioral measures included both the number of
lever presses and the amount of freely available laboratory chow that was
consumed. The specific treatments and testing times for each experiment
are listed below. Experiment 5 involved intracranial injections of tetra-
benazine; this experiment was a between-groups design, with each ani-
mal receiving only one treatment.
Experiment 1: Effects of systemic administration of theVMAT-2 inhibitor
tetrabenazine on the concurrent FR5/chow-feeding procedure. Rats were
trained until stable baseline performance was achieved (i.e., lever presses
consistently1200 per session). During the experiment, all animals (n
8) received intraperitoneal injections of the following treatments: 10%
DMSO vehicle and 0.25, 0.5, 0.75, and 1.0 mg/kg tetrabenazine. Injec-
tions were given 90 min before the beginning of the testing session.
Experiment 2: Effects of systemic administration of tetrabenazine on free
food intake and preference. Rats were trained the same two foods used in
the operant behavior experiments (Bio-serv pellets and laboratory chow)
until stable baseline performance was achieved (i.e., food consumption
10 g). During the experiment, all animals (n 8) received intraperito-
neal injections of the following treatments: 10%DMSO vehicle and 0.25,
0.5, 0.75, and 1.0 mg/kg tetrabenazine. Injections were given 90 min
before the beginning of the testing session.
Experiment 3: Effects of systemic administration of tetrabenazine on the
concurrent FR5/chow-feeding procedure: reversal with MSX-3. Rats were
trained as described above, and then all animals (n  8) received intra-
peritoneal injections of the following combined treatments: 10%DMSO
vehicle (90 min before testing) plus saline vehicle (20 min before
testing), 0.75 mg/kg tetrabenazine (90 min) plus saline vehicle (20
min), 0.75 mg/kg tetrabenazine (90 min) plus 0.5 mg/kg MSX-3 (20
min), 0.75 mg/kg tetrabenazine (90 min) plus 1.0 mg/kg MSX-3
(20 min), and 0.75 mg/kg tetrabenazine (90 min) plus 2.0 mg/kg
MSX-3 (20 min).
Experiment 4: Effects of systemic administration of tetrabenazine on the
concurrent FR5/chow-feeding procedure: reversal with bupropion. Rats
were trained as described above, and then all animals (n 11) received
intraperitoneal injections of the following combined treatments: 10%
DMSO vehicle (90 min before testing) plus saline vehicle (30 min before
testing), 0.75mg/kg tetrabenazine (90min)plus saline vehicle (30min), 0.75
mg/kg tetrabenazine (90 min) plus 5.0 mg/kg bupropion (30 min), 0.75
mg/kg tetrabenazine (90 min) plus 10.0 mg/kg bupropion (30 min), and
0.75mg/kg tetrabenazine (90min) plus 15.0 mg/kg bupropion (20min).
Experiment 5: Behavioral effects of tetrabenazine locally administered
into the nucleus accumbens core.All animals (N 24) were trained until a
stable baseline performancewas achieved (i.e., lever presses1200). Rats
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were then implanted with bilateral cannulae targeted at the accumbens
core (n 19) or a medial neostriatal control site dorsal to the core (n
5). After recovery from surgery and retraining, rats with accumbens core
placements received bilateral injections of vehicle (n 7) or 10.0g (n
5) or 20.0 g of tetrabenazine (n  7). Animals with dorsal control
placements received 20.0g of tetrabenazine. All injections were given in
a total volume of 0.5 l per side and rats were tested 15 min after drug
infusion. This experiment (and Experiment 6) focused on nucleus ac-
cumbens core because of previous research showing that the accumbens
core is the most effective striatal site at which DA depletion and inacti-
vation produce effects on effort-related choice behavior (Cousins et al.,
1993; Sokolowski and Salamone, 1998; Ghods-Sharifi and Floresco,
2010); furthermore, this is a highly effective site for the actions of D2
antagonists (Farrar et al., 2010) and adenosine A2A receptor agonists and
antagonists (Font et al., 2008; Mingote et al., 2008; Farrar et al., 2010) on
effort-related functions.
Neurochemical experiments
Neurochemical experiments were conducted to determine the effects of a
behaviorally active dose of tetrabenazine (0.75 mg/kg; see Experiments
3–4 above) on extracellular DA and DA-related markers of signal trans-
duction (c-Fos and pDARPP-32).
Experiment 6: Effect of tetrabenazine on extracellular DA in nucleus
accumbens. Rats were implanted with dialysis probes in nucleus ac-
cumbens core as described above. On the test day, they received in-
traperitoneal injections of either vehicle (n  5) or 0.75 mg/kg
tetrabenazine (n  6).
Experiments 7 and 8: Effect of tetrabenazine on cFos and pDARPP-32
expression in nucleus accumbens: reversal with MSX-3. On the test day,
untrained rats received intraperitoneal injections of vehicle (n  16),
0.75 mg/kg tetrabenazine (n 16), or 0.75 mg/kg tetrabenazine plus 2.0
mg/kg MSX-3 (n  16). Of these animals, half in each condition were
used for the cFos experiment and were killed 90 min after injection, and
the other half were used for the pDARPP-32 experiment and killed 45
min after injection. Immunocytochemical methods were used to analyze
tissue sections as described above.
Experiment 9: Effect of tetrabenazine on pDARPP-32(Thr34) and
pDARPP-32(Thr75) expression in substance-P- and enkephalin-positive
neurons in nucleus accumbens: immunofluorescence double labeling. Rats
received intraperitoneal injections of 0.75 mg/kg tetrabenazine (n 6).
Immunofluorescence double-labeling methods were used to analyze tis-
sue sections as described above to determine the peptides that coexpress
with neurons that express pDARPP-32(Thr34) andpDARPP-32(Thr75).
Statistical analyses
In Experiments 1, 3, and 4, lever presses and gram quantity of chow
intake from the 30 min sessions were analyzed with repeated-measures
ANOVA. For the food preference study (Experiment 2), the total quan-
tity of Bio-Serv pellets and chow were analyzed with factorial ANOVA.
Experiment 5 was analyzed using between-groups ANOVA. In Experi-
ments 1 and 5, nonorthogonal planned comparisons using the overall
error termwere used to compare each treatment with the vehicle control
condition (Keppel, 1991). For these comparisons, the  level was kept at
0.05 because the number of comparisons was restricted to the number of
treatmentsminus one. In Experiments 3 and 4, each condition that com-
bined tetrabenazine plus MSX-3 or bupropion was compared with the
tetrabenazine/vehicle condition using nonorthogonal planned compar-
isons. Changes in extracellular DA levels in themicrodialysis experiment
were calculated as the percentage change from baseline, with themean of
the two samples immediately preceding the lever pressing session serving
as the 100% baseline level. A factorial ANOVA with repeated measures
on the sample factor was used to test for differences in extracellular levels
of DA. The raw DA levels of the baseline samples were analyzed using t
test to verify that the baseline DA levels were not different between con-
ditions. For the cFos immunohistochemistry experiment, a between-
subjects ANOVA was used and planned comparisons were used to
determine pairwise differences between treatments. For Experiment 8,
data for each phosphorylated form of DARPP-32 (i.e., Thr34 and Thr75)
were analyzed separately with a brain area (core vs shell)  drug treat-
ment factorial ANOVA, with repeatedmeasures on the brain area factor.
When there was a significant area treatment interaction, these analyses
were followedby separate analyses of each area andpost hoc comparisons
with the Tukey test ( 0.05).
Results
Experiment 1: Effects of systemic administration of the
VMAT-2 inhibitor tetrabenazine on the concurrent FR5/
chow-feeding procedure
Systemic administration of tetrabenazine significantly decreased le-
verpressingandproducedaconcurrent increase in theconsumption
of the freely available laboratory chow, as shown inFigure1,AandB.
ANOVA revealed a significant effect of dose on lever pressing
(F(4,28)45.9,p	0.001).Therewas also anoverall significant effect
of drug treatment on chow intake (F(4,28)  33.8, p 	 0.001).
Planned comparisons were performed and showed that the two
highest doses of tetrabenazine significantly decreased lever pressing
Figure 1. Behavioral effects of tetrabenazine. A, Mean (SEM) number of lever presses
after treatment with vehicle and various doses of tetrabenazine (n 8). B, Mean (SEM)
intake of laboratory chow (in grams) after treatment with vehicle and various doses of tetra-
benazine. *p	 0.05, different from vehicle, planned comparison. C, Mean (SEM) intake of
Bio-serv pellets and laboratory chow (in grams) after treatment with vehicle and various doses
of tetrabenazine (n 8).
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and increased the consumption of the freely
available laboratory chow relative to control
(p	 0.05).
Experiment 2: Effects of systemic
administration of tetrabenazine on free
food intake and preference
The results of Experiment 2 are shown in
Figure 1C. There was a significant differ-
ence between food type consumed, with
rats preferring the Bio-serv pellets over
the standard laboratory chow (F(1,14) 
661; p 	 0.001). However, there was no
significant effect of drug treatment on
food intake (p 0.05) and no significant
drug treatment  food type interaction
(p 0.05).
Experiments 3 and 4: Effects of systemic
administration of the tetrabenazine on
the concurrent FR5/chow-feeding
procedure: reversal withMSX-3 and
bupropion
The results of Experiment 3 are shown in
Figure 2, A and B. MSX-3 was able to at-
tenuate the behavioral effects of tetra-
benazine. There was an overall significant
effect of drug treatment on lever pressing
(F(4,28) 26.8, p	 0.001). There was also
an overall significant effect of drug treat-
ment on chow intake (F(4,28)  40.5, p 	
0.001). Planned comparisons were per-
formed and showed that tetrabenazine
suppressed lever pressing and increased
chow intake and that all doses of MSX-3
were able to attenuate the effects of tetra-
benazine both on lever pressing and con-
sumption of the freely available
laboratory chow relative to the tetra-
benazine alone condition (p 	 0.05).
As shown in Figure 2, C and D, the
antidepressant bupropion was able to at-
tenuate the behavioral effects of tetrabenazine. There was an
overall significant effect of drug treatment on lever pressing
(F(4,40) 19.4, p	 0.001) and also an overall significant effect of
drug treatment on chow intake (F(4,40)  46.3, p 	 0.001).
Planned comparisons showed that, as in the previous two exper-
iments, 0.75 mg/kg tetrabenazine decreased lever pressing and
increased chow intake. In addition, the two highest doses of bu-
propion significantly increased lever pressing and also decreased
the consumption of the freely available laboratory chow relative
to the tetrabenazine condition (p	 0.05).
Experiment 5: Effects of tetrabenazine locally administered
into the nucleus accumbens core on the concurrent FR5/
chow-feeding procedure
Results of Experiment 5 are shown in Figure 3. There was an
overall significant effect of drug treatment on lever pressing
(F(3,23) 16.9, p	 0.001) and also on chow intake (F(3,23) 22.2,
p 	 0.001. Planned comparisons showed that accumbens core
injections of the highest dose of tetrabenazine produced a signif-
icant effect on lever pressing and chow consumption compared
with vehicle (p	 0.05). Injection of 20.0g of tetrabenazine into
the neostriatal control site dorsal to the accumbens core did not
alter lever pressing or chow intake compared with vehicle, but
this group did differ on bothmeasures from the rats that received
the same dose into the nucleus accumbens (p	 0.05, Tukey test).
Experiment 6: Effect of tetrabenazine on extracellular DA in
nucleus accumbens
Figure 4A summarizes the results of the microdialysis experi-
ment. The vehicle (n 5) and 0.75 mg/kg tetrabenazine (n 6)
groups did not differ in terms of baseline levels of extracellular
DA (mean  SEM DA expressed as picograms/sample; vehicle:
27.5  8.1; tetrabenazine: 21.6  4.5; t  0.55, df  9, p  0.5,
NS). Factorial ANOVA across all 9 samples (Fig. 4A) demonstrated
that there was a significant effect of drug treatment (F(1,9)  8.1,
p	 0.05), a significant difference across samples (F(8,72) 3.53,
p 	 0.05), and a significant treatment  sample interaction
(F(8,72)  2.3, p 	 0.05). Separate analyses of each treatment
group showed that there was no significant change over samples
in the vehicle group (F(8,32) 0.192, p 0.9, NS), but there was
a significant change inDA levels across samples for the tetrabena-
zine group (F(8,40)  5.81, p 	 0.001). Planned comparisons
showed that animals injected with 0.75 mg/kg tetrabenazine had
Figure 2. The effects of the adenosine A2A antagonist MSX-3 and the antidepressant bupropion on tetrabenazine-induced
changes in performance on the concurrent lever pressing/chow-feeding procedure. A, B, Tetrabenazine and MSX-3. Rats (n 8)
received intraperitoneal injections of vehicle plus vehicle (Veh/Veh), 0.75 mg/kg tetrabenazine plus vehicle (TBZ/Veh), or tetra-
benazine plus 0.25, 0.5, 1.0, or 2.0mg/kg doses ofMSX-3 (M).A, Mean (SEM) number of lever presses (FR5 schedule) during the
30 min session. B, Mean (SEM) gram quantity of chow intake. C, D, Tetrabenazine and bupropion. Rats (n 11) received
intraperitoneal injections of vehicle plus vehicle (Veh/Veh), 0.75 mg/kg tetrabenazine plus vehicle (TBZ/Veh), or tetrabenazine
plus 5.0, 10.0, or 15.0mg/kg doses of bupropion (BU). C, Mean (SEM) number of lever presses (FR5 schedule) during the 30min
session. D, Mean (SEM) gram quantity of chow intake. #p 	 0.05, tetrabenazine plus vehicle significantly differed from
vehicle/vehicle; *p	 0.05, significantly different from tetrabenazine plus vehicle.
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significantly lower levels of extracellular DA in samples D4-D7
relative to the last baseline sample (p	 0.05).
Experiments 7–9: Tetrabenazine affects the DA-related signal
transductionmarkers cFos and DARPP-32
The results of immunocytochemistry experiments are shown in
Figure 4, B–D, and Figure 5. There was an overall effect of drug
treatment on the number of cFos positive cell in nucleus accum-
bens core (F(2,23) 73.0, p	 0.001; Fig. 4B). Planned compari-
sons showed that tetrabenazine increased cFos-positive cells
counts relative to vehicle alone (p	 0.05) and that the combina-
tion of tetrabenazine plus MSX-3 differed significantly from tet-
rabenazine plus vehicle (p	 0.05). In Experiment 8, analyses of
pDARPP-32(Thr34) immunoreactivity (Fig. 4C) showed that
there was no overall difference between core and shell (F(1,21)
0.5, NS), but there was an overall effect of drug treatment on the
number of pDARPP-32(Thr34)-positive cells (F(2,21)  87.72,
p	 0.05) and a significant brain area drug treatment interac-
tion (F(2,21) 6.18, p	 0.05). Separate ANOVAs of core and shell
revealed that the drug treatment effects were significant in both
areas (p 	 0.05) and planned comparisons revealed that tetra-
benazine produced a significant increase in pDARPP-32(Thr34)
expression (p 	 0.05) in both areas, which was suppressed by
coadministration of MSX-3 (p 	 0.05). However, the source of
the interaction was that MSX-3 produced a greater suppression
of tetrabenazine-induced expression of pDARPP-32(Thr34) in
the core relative to shell (p 	 0.05). There was also an overall
effect of drug treatment on the number of pDARPP-32(Thr75)-
positive cells (F(2,21) 72.5, p	 0.05; Fig. 4D), but no significant
core versus shell difference (F(1,21) 1.5,NS) andnobrain area
treatment interaction (F(2,21)  1.8, NS). Collapsed across both
regions, tetrabenazine produced an overall increase in pDARPP-
32(Thr75) expression (p 	 0.05), but MSX-3 failed to suppress
the tetrabenazine-induced increase in pDARPP-32(Thr75)-
positive cells. Figure 5 shows the results of the immunofluores-
cence double-labeling study. In animals treated with 0.75 mg/kg
tetrabenazine, pDARPP-32(Thr34) was coexpressed with en-
kephalin, but not substance P, whereas pDARPP-32(Thr75) was
coexpressed with substance P, but not enkephalin. Together with
the results of the single-labeling experiment (Fig. 4B,C), this
pattern of results is consistent with a reduction of D1 and D2
receptor signaling induced by tetrabenazine.
Discussion
These experiments assessed the effort-related motivational ef-
fects of the VMAT-2 inhibitor tetrabenazine. Animals show ro-
bust activation in the initiation and maintenance of motivated
behavior (Salamone and Correa, 2002, 2012; Berridge and Rob-
inson, 2003; Robbins and Everitt, 2007; Nicola, 2010; McGinty et
al., 2013) and demonstrate substantial and persistent work out-
put in their instrumental actions. Moreover, they frequently
make effort-related decisions, allocating behavioral resources in
relation to the motivational value of stimuli and the effort re-
quired to obtain them (Salamone and Correa, 2012). The present
experiments used the FR5/chow-feeding task as a measure of
effort-related choice behavior (Salamone et al., 1991, 1997;
Nunes et al., 2010). This task is sensitive to the effects of D1 or D2
antagonism and accumbens DA depletions (Salamone et al.,
1991, 2002; Cousins et al., 1994; Nowend et al., 2001; Sink et al.,
2008; Farrar et al., 2010). Furthermore, the effects of interference
with DA transmission on this task are not due to changes in
appetite, food intake, or preference (Salamone et al., 1991; Koch
et al., 2000) and do not resemble the effects of reinforcer devalu-
ation by prefeeding (Salamone et al., 1991) or appetite suppres-
sant drugs (Cousins et al., 1994; Salamone et al., 2002; Sink et al.,
2008). As shown above, tetrabenazine shifted choice behavior,
decreasing lever pressing but increasing consumption of the con-
currently available chow. In a parallel experiment, the same doses
of tetrabenazine had no effect on food intake or preference for
high carbohydrate pellets over chow. Therefore, tetrabenazine-
induced shifts in effort-related choice were not due to changes in
primary foodmotivation, the unconditioned reinforcing proper-
ties of food, or food preference. Although tetrabenazine exerted a
selective effect on the tendency towork for food by lever pressing,
tetrabenazine-treated rats remained directed toward food acqui-
sition and consumption and selected an alternative path to obtain
food (i.e., approach/consumption of the concurrently available
Figure3. Intracranial administration of tetrabenazine.A, Placements of cannulae in nucleus
accumbens core (filled circles) and the dorsal control site (open circles) in rats that received the
20.0g dose of tetrabenazine.B, Mean (SEM) number of lever presses after treatmentwith
either vehicle (n 7), 10.0g (n 5), or 20.0g (n 7) per side of tetrabenazine injected
into nucleus accumbens core or 20.0g per side injected into the dorsal control site (n 5). C,
Mean (SEM) intake of laboratory chow (in grams) after treatment with vehicle, 10.0g or
20.0g per side of tetrabenazine injected into nucleus accumbens core, or 20.0g per side
injected into the dorsal control site. *p	 0.05, different from vehicle, planned comparison.
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chow). This conclusion is consistent with
preliminary studies demonstrating that
tetrabenazine also reduced selection of
the high effort/high reward option in
rats tested on a T-maze barrier choice
task (Yohn et al., 2012) and a progres-
sive ratio/chow feeding choice proce-
dure (Salamone et al., 2012). Injections
of tetrabenazine into accumbens core
also reduced FR5 lever pressing and in-
creased chow intake (Fig. 3), whereas
injections into a medial neostriatal con-
trol site dorsal to accumbens were inef-
fective. This is consistent with previous
studies linking effort-related choice be-
havior to accumbens DA (Salamone et
al., 1991; Cousins et al., 1993; Nowend
et al., 2001; Farrar et al., 2010; Mai et al.,
2012; Trifilieff et al., 2013).
Tests of effort-related choice behav-
ior may have utility as preclinical mod-
els of motivational symptoms such as
psychomotor retardation, anergia, and
fatigue, which are seen in depression and
otherdisorders (Salamone et al., 2006, 2007,
2010; Salamone and Correa, 2012). This
idea is consistent with human studies of
effort-related decisionmaking showing that
decreased selection of high effort/high re-
ward options is seen in patients with major
depression (Treadwayet al., 2012b)andalso
in schizophrenics with a preponderance of
negative symptoms (Gold et al., 2013). Be-
cause tetrabenazine produces depressive
symptoms including psychomotor slowing
and fatigue in humanpatients (Frank, 2009;
Guay, 2010; Chen et al., 2012), the adeno-
sine A2A antagonist MSX-3 and the cate-
cholamine uptake blocker bupropion were
assessed for their ability to reverse the be-
havioral effects of tetrabenazine. Adenosine
A2A antagonists produce behavioral effects
in animals that are consistent with antide-
pressant actions (Hodgson et al., 2009;
Hanff et al., 2010), andbupropion (Wellbu-
trin) is a widely used antidepressant drug
(Milea et al., 2010) that can produce
antidepressant-like effects in rodent tasks
such as the forced swim and tail suspension
tests (Bourin et al., 2005; Kitamura et al.,
2010). MSX-3 fully reversed the effects of
tetrabenazine on FR5/chow-feeding choice
performance, which is consistent with research demonstrating that
adenosineA2A antagonists reverse the effects ofDAD2 family antag-
onists on effort-related choice behavior (Farrar et al., 2007;Mott et
al., 2009; Salamone et al., 2009; Worden et al., 2009; Nunes et al.,
2010; Santerre et al., 2012). Bupropion, a catecholamine uptake
blocker that elevates extracellular DA and norepinephrine (Hud-
son et al., 2012), also reversed the effort-related effects of tetra-
benazine. It is not clear which catecholamine mediates this
action, but there is little evidence implicating norepinephrine in
effort-related choice and considerable evidence supporting a role
for DA (Salamone et al., 2007). Nevertheless, in view of the
known antidepressant actions of bupropion in humans, these
results validate the hypothesis that tests of effort-related choice
behavior can be used to assess some of the motivational effects of
antidepressant drugs. Furthermore, these results are consistent
with clinical data indicating that bupropion is relatively effective
for treating psychomotor retardation and fatigue symptoms of
depression (Fabre et al., 1983; Pae et al., 2007) and can be more
effective than other antidepressants, including 5-HT uptake
blockers, for treating motivational dysfunction in depressed pa-
tients (Papakostas et al., 2006).
Figure4. Neurochemical effects of tetrabenazine.A,Microdialysis data showing theeffect of 0.75mg/kg tetrabenaineonmean
(SEM)extracellularDA (expressedaspercentageofbaseline) innucleusaccumbens core. Samples (30min)were collectedduring
the baseline period (BL1 and BL2) and for the 7 samples after the injection of either tetrabenazine (n 6) or vehicle (n 5)
(D1–D7). *p	 0.05, different from last baseline sample in the tetrabenazine group. B, Expression of c-Fos immunoreactivity in
nucleus accumbens core. Mean (SEM) number of c-Fos-positive cells in the accumbens and core after injection of vehicle plus
vehicle (Veh/Veh; n 8), 0.75 mg/kg tetrabenazine plus vehicle (TBZ/Veh; n 8), or tetrabenazine plus the 2.0 mg/kg dose of
MSX-3 (n8). #p	0.05, tetrabenazine plus vehicle significantly differed fromvehicle/vehicle; *p	0.05, significantly different
from tetrabenazine plus vehicle. C, Expression of pDARPP-32(Thr34) immunoreactivity in nucleus accumbens core and shell after
injection of vehicle plus vehicle (Veh/Veh; n 8), 0.75mg/kg tetrabenazine plus vehicle (TBZ/Veh; n 8), or tetrabenazine plus
the 2.0 mg/kg dose of MSX-3 (n 8). Left, Photomicrographs of individual animals. Right, Mean SEM number of pDARPP-
32(Thr34)-positive cells. #p	 0.05, tetrabenazine plus vehicle significantly differed fromvehicle/vehicle; *p	 0.05, significantly
different from tetrabenazine plus vehicle;TBZ plus MSX-3 in core significantly differed from TBZ plus MSX-3 in shell. D, Expres-
sion of pDARPP-32(Thr75) immunoreactivity in nucleus accumbens core and shell after injection of vehicle plus vehicle (Veh/Veh;
n 8), 0.75mg/kg tetrabenazine plus vehicle (TBZ/Veh; n 8), or tetrabenazine plus the 2.0mg/kg dose ofMSX-3 (n 8). Left,
Photomicrographs of individual animals. Right, Mean SEM number of pDARPP-32(Thr75) positive cells. #Tetrabenazine plus
vehicle significantly differed from vehicle/vehicle across both core and shell.
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Figure 5. A, Left, Diagram showing effect of DA on DARPP-32 phophorylation (for details, see Svenningsson et al., 2004; Bateup et al., 2008; Yger and Girault, 2011). D1 receptor stimulation
increases c-AMPproduction andprotein kinaseA (PKA) activity,whichphosphorylatesDARPP-32 to yield pDARPP-32(Thr34). D2 receptor stimulationdecreases c-AMPproduction andprotein kinase
A activity, which decreases the dephosphorylation of pDARPP-32(Thr75) by protein phosphatase 2A (PP-2A) and therefore increases pDARPP-32(Thr75) expression. Right, Tetrabenazine, which
depletes DA, was hypothesized to have the opposite effect of DA, increasing pDARPP-32(Thr75) in substance-P-positive neurons and pDARPP-32(Thr34) in (Figure legend continues.)
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Tetrabenazine substantially reduced extracellular DA in ac-
cumbens core as measured by microdialysis and also affected
DA-related signal transduction in a manner consistent with re-
duced accumbens D1 and D2 receptor transmission. Tetrabena-
zine increased cFos immunoreactivity in accumbens core and
shell, which is consistent with a reduction in D2 transmission
(Robertson et al., 1992; Santerre et al., 2012). Furthermore, im-
munocytochemistry of different forms of phosphorylated
DARPP-32 indicated that 0.75 mg/kg tetrabenazine significantly
increased accumbal expression of both pDARPP-32(Thr34) and
pDARPP-32(Thr75). Previous results suggest that tetrabenazine-
induced increases in pDARPP-32(Thr75) would reflect reduced
transmission at DA D1 family receptors, whereas the increase in
pDARPP-32(Thr34) wouldmark reduced transmission at DAD2
family receptors (Svenningsson et al., 2004; Bateup et al., 2008;
Yger andGirault, 2011; Santerre et al., 2012). These DA receptors
are largely localized on separate populations of medium spiny
neurons, so immunofluorescence double-labeling studies for
both forms of pDARPP-32were conducted to determinewhether
there was coexpression with either substance P (marking D1-
receptor-containing cells) or enkephalin (marking D2-receptor-
containing cells; Segovia et al., 2012). These double-labeling
studies confirmed that, in tetrabenazine-treated rats, pDARPP-
32(Thr75) expression was in substance-P-positive cells, whereas
pDARPP-32(Thr34) expression was in enkephalin-positive cells.
Interestingly, MSX-3 attenuated the effects of tetrabenazine on
pDARPP-32(Thr34) expression, but not pDARPP-32(Thr75) ex-
pression. This is consistent with studies showing that adenosine
A2A receptors are colocalized with D2 receptors on enkephalin-
positive neurons, but not with D1 receptors on substance-P-
positive neurons (Svenningsson et al., 1999), and that A2A andD2
receptors can form heteromers and interact via convergence
onto c-AMP signal transduction cascades (Ferre´ et al., 2008). The
suppression of tetrabenazine-induced increases in pDARPP-
32(Thr34) expression by MSX-3 was greater in the core versus the
shell, which may be due to a lower level of adenosine A2A receptor
expression in the shell (Rosin et al., 1998; Ishiwari et al., 2007).
By inhibiting VMAT-2, tetrabenazine affects monoamine
storage, but studies indicate that the greatest effects are on striatal
DA. A study of postmortem tissue of humans receiving clinical
doses of tetrabenazine reported that the only statistically signifi-
cant depletions were DA in the caudate, norepinephrine in the
amygdala, and norepinephrine and DA in the hippocampus
(Guay, 2010). Pettibone et al. (1984) showed that 1.0 mg/kg tet-
rabenazine reduced striatal DA in rats by 
75% while reducing
5-HT and norepinephrine by 
15–30%, and observed that a
dose of 10.0 mg/kg tetrabenazine was needed to reduce 5-HT as
much as 1.0 mg/kg depleted striatal DA. Similar results were
shown by Tanra et al. (1995), who reported that 1.0 mg/kg tetra-
benazine reduced striatal DA in rats by 57%, whereas with 5-HT,
there were no significant reductions in frontal cortex, striatum,
or hippocampus and only a 20% reduction in hypothalamus. No
studies specifically demonstrate a role for norepinephrine in
effort-related decision making, but one report indicates that de-
pletion of 5-HT does not affect performance in rats responding
on the T-maze barrier choice task (Denk et al., 2005). Together
with the present results, these studies support the hypothesis that
the effects of tetrabenazine on effort-related choice are largely
due to actions on DA.
In summary, tetrabenazine alters effort-related choice behav-
ior, reducing food-reinforced lever pressing and biasing animals
toward selection of the freely available chow at doses that did not
affect food preference or consumption. The ability of tetrabena-
zine to affect effort-based decision making is consistent with
research showing that other manipulations associated with de-
pression, including stress (Shafiei et al., 2012) and administration
of proinflammatory cytokines (Nunes et al., 2003b), can alter
effort-based choice. The behavioral effects of tetrabenazine were
attenuated by coadministration of an adenosine A2A antagonist
and the antidepressant bupropion. Future research should study
the effort-related effects of additional antidepressant drugs with
different pharmacological profiles. Consistent with studies dem-
onstrating DAergic involvement in effort-related processes and
with research implicating DA in motivational symptoms of de-
pression (Rampello et al., 1991; Brown and Gershon, 1993;
Treadway and Zald, 2011; Argyropoulos and Nutt, 2013; Soskin
et al., 2013), tetrabenazine reduced extracellular DA and
altered DARPP-32 signaling in both substance-P- and enkephalin-
containing accumbens neurons. This research could have implica-
tions for understanding the neural circuits underlying effort-related
motivational dysfunctions in depression, schizophrenia, and other
disorders.
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